Top

Published in:

01-03-2014 | Research Article

Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma

Authors: Qing-Feng Kong, Jun-Bo Jiao, Qian-Qian Chen, Long Li, Dong-Guang Wang, Bin Lv

Published in: Tumor Biology | Issue 3/2014

Abstract

The aim of this study is to compare the overall survival in patients with hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) versus RFA alone. All eligible studies were collected from the PubMed, the Cochrane Library, and the Embase electronic databases. The outcomes were overall survival rates. We used odds ratios to assess the strength of the association, and 95 % confidence intervals give a sense of the precision of the estimate. Statistical analyses were performed by Review Manager 5.0 and Stata 11.0. A total of 19 available studies were considered in the present meta-analysis. When all groups were pooled, meta-analysis showed that RFA plus TACE significantly improved the survival rates of patients with HCC at 1, 3, and 5 years compared with RFA alone. The combination of RFA with TACE has advantages in improving overall survival rate, and provides better prognosis for HCC patients.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef

Guo D, Hou X, Zhang H, Sun W, Zhu L, Liang J, et al. More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, supressed invasion of HepG2 and HCCLM3 cells. J Exp Clin Cancer Res. 2011;30:9.CrossRef

Abdel aziz MT, El Asmar MF, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, et al. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling. J Exp Clin Cancer Res. 2011;30:49.PubMedCentralPubMedCrossRef

Li FQ, Zhang SX, An LX, Gu YQ. In vivo molecular targeting effects of anti-Sp17- ICG-Der-02 on hepatocellular carcinoma evaluated by an optical imaging system. J Exp Clin Cancer Res. 2011;30:25.PubMedCentralPubMedCrossRef

Tveteraas IH, Müller KM, Aasrum M, Ødegård J, Dajani O, Guren T, et al. Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells. J Exp Clin Cancer Res. 2012;31:72.PubMedCentralPubMedCrossRef

Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.PubMedCentralPubMedCrossRef

Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology. 2004;127:1714–23.PubMedCrossRef

Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–30.PubMedCrossRef

Lu DS, Yu NC, Raman SS, Limanond P, Lassman C, Murray K, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology. 2005;234:954–60.PubMedCrossRef

10.

Yang W, Chen MH, Wang MQ, Cui M, Gao W, Wu W, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res. 2009;39:231–40.PubMedCrossRef

11.

Peng ZW, Chen MS, Liang HH, Gao HJ, Zhang YJ, Li JQ, et al. A case–control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol. 2010;36:257–63.PubMedCrossRef

12.

Hu YQ. Radiofrequency ablation and transcatheter arterial chemoembolization in primary hepatic carcinoma. Contemp Med. 2011;17:232–3.

13.

Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, et al. Hepatocellular carcinomas 2–3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Eur J Radiol. 2012;81:e189–93.PubMedCrossRef

14.

Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB, et al. Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol. 2011;18:1624–9.PubMedCrossRef

15.

Shen SQ, Xiang JJ, Xiong CL, Wu SM, Zhu SS. Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC. Hepatogastroenterology. 2005;52:1403–7.PubMed

16.

Kang CB, Xu HB, Wang SL, Rui B. Treatment of large hepatoma by TACE in combination with RFA. Chin J Hepatobiliary Surg. 2007;13:828–30.

17.

Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation. Ai Zheng. 2005;24:827–33.PubMed

18.

Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA, and TACE in HCC. Adv Ther. 2008;25:787–94.PubMedCrossRef

19.

Xu L, Li P, Chen MS, Pang XH, Gao HJ, Peng ZW, et al. Percutaneous radiofrequency ablation combined with other minimally invasive treatments for recurrent hepatocellular carcinoma after hepatectomy. Zhonghua Wai Ke Za Zhi. 2008;46:1617–20.PubMed

20.

Luo ZG, Xiong K, Duan QW, Ren JM, Wang DW, Li C. Therapy of 3-dimension conform technology-guided radiofrequency ablation and transcatheter arterial chemoembolization in primary hepatic carcinoma. Yunyang Yi Xue Yuan Xue Bao. 2008;27:22–5.

21.

Li ZR, Kang Z, Qian JS, Zhu KS, Jiang ZB, Huang MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization for management of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27:1749–51.PubMed

22.

Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009;252:905–13.PubMedCrossRef

23.

Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299:1669–77.PubMedCrossRef

24.

Aikata H, Shirakawa H, Takaki S. Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatology. 2006;44:A487.CrossRef

25.

Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for deter-mining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116:5452–60.PubMedCrossRef

26.

Shen L, Chen MH, Yan K, Yang W, Gao W, Liao SR, et al. Clinical application of a combination therapy of percutaneous radiofrequency and transcatheter arterial chemoembolization in large hepatic tumors. Zhonghua Chao Sheng Yin Xiang Xue Za Zhi. 2004;13:577–80.

27.

Zhang HC, Liang J. Radiofrequency ablation or transcatheter arterial chemoembolization for management of hepatocellular carcinoma. Zhong Guo Yi Shi Jin Xiu Za Zhi. 2007;30:67–8.

28.

Liang MH. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the management of hepatocellular carcinoma. Zhong Guo Lao Nian Yi Xue Za Zhi. 2011;31:2862–4.

29.

Zhang H, Qi C, Li L, Luo F, Xu Y. Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res. 2013;32:56.PubMedCentralPubMedCrossRef

30.

Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, et al. Prognostication of prostate cancer based on NUCB2 protein assessment. NUCB2 in prostate cancer. 2013;32:77.

31.

Zhang H, Ma H, Xu Y, Li L. Association of SMAD7 rs12953717 polymorphism with cancer: a meta-analysis. PLoS ONE. 2013;8:e58170.PubMedCentralPubMedCrossRef

32.

Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One. 2013;8:e69366.PubMedCentralPubMedCrossRef

33.

Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRef

34.

Zhang H, Li L, Xu Y. CYP1B1 polymorphisms and susceptibility to prostate cancer: a meta-analysis. PLoS One. 2013;8:e68634.PubMedCentralPubMedCrossRef

35.

Li GC, Ye QH, Dong QZ, Ren N, Jia HL, Qin LX. TGF beta1 and related-Smads contribute to pulmonary metastasis of hepatocellular carcinoma in mice model. J Exp Clin Cancer Res. 2012;31:93.PubMedCentralPubMedCrossRef

36.

You N, Liu W, Tang L, Zhong X, Ji R, Zhang N, et al. Tg737 signaling is required for hypoxia-enhanced invasion and migration of hepatoma cells. J Exp Clin Cancer Res. 2012;31:75.PubMedCentralPubMedCrossRef

37.

Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, et al. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res. 2012;31:26.PubMedCentralPubMedCrossRef

38.

Yu XC, Xu M, Xu SF, Song RX. Long-term outcomes of epiphyseal preservation and reconstruction with inactivated bone for distal femoral osteosarcoma of children. Orthop Surg. 2012;4(1):21–7.PubMedCrossRef

39.

Hu YC, Ji JT, Lun DX. Intraoperative microwave inactivation in situ of malignant tumors in the scapulas. Orthop Surg. 2011;3(4):229–35.PubMedCrossRef

Title: Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma
Authors: Qing-Feng Kong
Jun-Bo Jiao
Qian-Qian Chen
Long Li
Dong-Guang Wang
Bin Lv
Publication date: 01-03-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1349-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Expression and clinical significance of STIP1 in papillary thyroid carcinoma

Association of MDR1 G2677T polymorphism and leukemia risk: evidence from a meta-analysis

Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies

Cerebral radiation injury and changes in the brain tissues of rat models with glioma

Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer

Effects of tetrandrine on glioma cell malignant phenotype via inhibition of ADAM17

Keynote webinar | Spotlight on antibody–drug conjugates in cancer